Translational research in our study showed that everolimus yielded direct and specific inhibition of the PI3K-AKT-mTOR pathway in tumor tissues with a significant decrease in p-S6K observed in a majority of post-treatment biopsies as compared to baseline biopsies. The gene discussed is MTOR; the disease is neoplasm.